X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs CIPLA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH CIPLA PANACEA BIOTECH/
CIPLA
 
P/E (TTM) x -21.1 40.6 - View Chart
P/BV x 2.5 3.7 66.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PANACEA BIOTECH   CIPLA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
CIPLA
Mar-18
PANACEA BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs149663 22.4%   
Low Rs82479 17.2%   
Sales per share (Unadj.) Rs84.1189.0 44.5%  
Earnings per share (Unadj.) Rs-18.317.6 -104.0%  
Cash flow per share (Unadj.) Rs-6.734.0 -19.7%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs83.7176.7 47.4%  
Shares outstanding (eoy) m61.25805.12 7.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.43.0 45.4%   
Avg P/E ratio x-6.332.5 -19.4%  
P/CF ratio (eoy) x-17.216.8 -102.7%  
Price / Book Value ratio x1.43.2 42.7%  
Dividend payout %017.1 0.0%   
Avg Mkt Cap Rs m7,074459,724 1.5%   
No. of employees `0002.823.6 11.6%   
Total wages/salary Rs m1,44926,901 5.4%   
Avg. sales/employee Rs Th1,874.16,446.1 29.1%   
Avg. wages/employee Rs Th527.01,139.4 46.3%   
Avg. net profit/employee Rs Th-407.7600.0 -68.0%   
INCOME DATA
Net Sales Rs m5,154152,193 3.4%  
Other income Rs m1003,577 2.8%   
Total revenues Rs m5,254155,769 3.4%   
Gross profit Rs m-76628,264 -2.7%  
Depreciation Rs m71113,228 5.4%   
Interest Rs m1,5031,142 131.6%   
Profit before tax Rs m-2,88117,470 -16.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-6-28 20.5%   
Extraordinary Inc (Exp) Rs m1,771-775 -228.4%   
Tax Rs m172,501 0.7%   
Profit after tax Rs m-1,12114,166 -7.9%  
Gross profit margin %-14.918.6 -80.1%  
Effective tax rate %-0.614.3 -4.1%   
Net profit margin %-21.89.3 -233.8%  
BALANCE SHEET DATA
Current assets Rs m3,810108,141 3.5%   
Current liabilities Rs m8,36538,322 21.8%   
Net working cap to sales %-88.445.9 -192.7%  
Current ratio x0.52.8 16.1%  
Inventory Days Days15697 160.5%  
Debtors Days Days6774 90.4%  
Net fixed assets Rs m14,480109,411 13.2%   
Share capital Rs m611,610 3.8%   
"Free" reserves Rs m903140,682 0.6%   
Net worth Rs m5,127142,292 3.6%   
Long term debt Rs m5,83236,621 15.9%   
Total assets Rs m19,433228,606 8.5%  
Interest coverage x-0.916.3 -5.6%   
Debt to equity ratio x1.10.3 441.9%  
Sales to assets ratio x0.30.7 39.8%   
Return on assets %2.06.7 29.3%  
Return on equity %-21.910.0 -219.7%  
Return on capital %3.610.0 36.5%  
Exports to sales %24.532.8 74.8%   
Imports to sales %10.20-   
Exports (fob) Rs m1,26449,883 2.5%   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53951,691 3.0%   
Fx outflow Rs m94221,033 4.5%   
Net fx Rs m59730,658 1.9%   
CASH FLOW
From Operations Rs m59914,628 4.1%  
From Investments Rs m-438-8,540 5.1%  
From Financial Activity Rs m-303-3,855 7.8%  
Net Cashflow Rs m-1412,431 -5.8%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.6 12.2 4.9%  
FIIs % 1.3 23.7 5.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.6 26.2 90.1%  
Shareholders   10,259 161,166 6.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 21, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS